Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. uri icon

Overview

authors

  • Roboz, Gail J
  • Yee, Karen
  • Verma, Amit
  • Borthakur, Gautam
  • de la Fuente Burguera, Adolfo
  • Sanz, Guillermo
  • Mohammad, Helai P
  • Kruger, Ryan G
  • Karpinich, Natalie O
  • Ferron-Brady, Geraldine
  • Acusta, Andre
  • Del Buono, Heather
  • Collingwood, Therese
  • Ballas, Marc
  • Dhar, Arindam
  • Wei, Andrew H

publication date

  • December 19, 2021

Research

keywords

  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes

Identity

Digital Object Identifier (DOI)

  • 10.1080/10428194.2021.2012667

PubMed ID

  • 34927529